Mendoza Juan Miguel

Director Mendoza buys 3,143 shares of HLF at $7.50; holds 170,000 shares post-transaction, extending recent buying pattern.

Mendoza purchased 3,143 shares at $7.50 on 2025-06-05, following a buy on 2025-05-22 and adding to a position that now totals 170,000 shares. The stock has risen 17.8% over 30 days but trades 36.5% below its 52-week high of $12.49, currently at $7.93. Reviewing his prior HLF trades, Mendoza's timing record at this ticker has been mixed: 0 of 3 measurable prior buys resulted in positive 90-day returns, with a prior buy on 2024-11-08 experiencing a 90-day loss of -36.8%. The company trades at a P/E of 2.88 with $1.2B in quarterly revenue but faces -1.4% annual revenue growth. The repeated purchases at depressed levels within two weeks suggest sustained accumulation, though the absence of positive longer-term outcomes on his prior HLF purchases warrants investor attention to whether current valuations represent genuine opportunity or persistence without validation.

Director Mendoza buys 5,000 HLF shares at $6.75; stock down 46.7% from 52-week high, P/E 2.42.

Director Juan Miguel Mendoza purchased 5,000 shares of Herbalife at $6.75 on 2025-05-22, increasing his holdings to 166,857 shares, a 3.1% addition. The purchase occurs with the stock trading at $6.66 currently, down 46.7% from its 52-week high of $12.49, and the company exhibits a low valuation multiple (P/E 2.42) alongside modest near-term momentum (+1.8% over 30 days, -19.9% over 90 days). However, his prior trades at HLF show mixed outcomes: two completed 90-day measurement windows both returned negative (90d returns of -36.8% and -33.8%), and across his cross-ticker buy history, the 90-day win rate stands at 42.86% with an average 90-day return of -3.2%, indicating a track record of timing challenges. This recent buy follows a pattern of repeated accumulation at this ticker (5 prior trades in less than 7 months), which warrants assessment of whether the insider sees fundamental value or is continuing a pattern of acquisitions that have not delivered positive returns on his prior similar-period holdings.

Director Mendoza buys 5,000 HLF shares at $6.73; stock now $6.86 but -45.1% from 52-week high

Mendoza Juan Miguel (Director) purchased 5,000 shares at $6.73 on 2025-05-02, increasing holdings to 161,857 shares (a 3.2% addition to his pre-transaction position). The transaction occurs as HLF trades -45.1% from its 52-week high of $12.49, with the stock down 17.0% over the prior 30 days despite a 26.8% 90-day gain. Mendoza's same-ticker history at HLF shows a mixed pattern: his two most recent purchases (2025-03-04 and 2025-02-27) have posted near-term gains of 5.8% and 3.9% respectively, but his three prior HLF acquisitions in November 2024 all resulted in substantial negative 90-day returns (-36.8%, -33.8%, -31.6%), with 0 of 3 being well-timed at the 90-day mark. The company fundamentals show contraction (annual revenue growth of -1.4% year-over-year) and a valuation of 2.49 P/E on $50.4M net income against $1.2B quarterly revenue, suggesting limited earnings cushion relative to size.

Director Mendoza buys 2,500 HLF shares at $8.00; holds 135,000 post-transaction. Stock at $8.82, down 29.4% from 52-week high.

Mendoza purchased 2,500 shares at $8.00 on 2025-03-04, adding to a substantial existing position of 132,500 shares. The stock has recovered strongly in the near term (+63.6% over 30 days) but remains sharply depressed relative to its 52-week high of $12.49 (-29.4%). Notably, his prior trades at HLF show a poor track record: of 4 prior measurable same-ticker purchases, only 1 generated a positive 90-day return, with an average 90-day outcome of -25.6% loss across those completed transactions. His cross-ticker track record is similarly weak, averaging -3.2% over 90 days with a 42.86% win rate. The timing of this purchase—after the stock has already staged a 63.6% month-over-month rebound—suggests accumulation at a point where the recovery may already be priced in.

Director Mendoza buys 5,000 HLF shares at $8.25 on 2025-02-27; stock now at $8.11, -35.1% from 52-week high.

Mendoza Juan Miguel, a Director, purchased 5,000 shares of Herbalife at $8.25 per share on 2025-02-27, boosting his holdings by 3.9% to 132,500 shares total. The transaction occurs while the stock trades at $8.11 current price, down 35.1% from its 52-week high of $12.49, though up 48.5% over the prior 30 days. His prior five purchases at HLF show mixed timing: only 1 of 5 achieved positive 90-day returns (the September 2024 buy returned +12.0%), while the most recent November 2024 buys experienced 90-day declines ranging from -31.6% to -36.8%, indicating difficulty capturing upside at this ticker. Against the company's weak fundamentals—annual revenue declined 1.4% year-over-year to $1.2B with a minimal P/E of 4.14—the transaction adds to an established pattern of accumulation that has not generated consistent positive returns.

Director Mendoza bought 2,500 shares of HLF at $8.49 on 2024-11-08, totaling $21,225.00; stock now $8.20, -46.8% from 52-week high.

Mendoza Juan Miguel, a Director, purchased 2,500 shares at $8.49 on 2024-11-08, bringing his holdings to 127,500 shares. The transaction represents a +2.0% increase to his position. At current price $8.20, the trade is underwater by 3.4%, and HLF is trading 46.8% below its 52-week high of $15.40. Mendoza has completed five purchases at HLF in recent months; his most recent same-ticker trades at this price level show mixed results, with one measurable 90-day outcome (+8.2% on the 2024-08-13 buy). His cross-ticker buy track record shows an average 90-day return of +5.3% across 13 prior buys with a 55.56% win rate, though this cross-ticker history does not necessarily predict HLF-specific outcomes. The stock's 30-day performance of +20.6% marks a recent rebound, yet year-to-date revenue growth of -2.7% and a low P/E of 9.53 provide limited fundamental support for sustained appreciation.

Director Juan Miguel Mendoza purchases 5,000 HLF shares in 2 tranches for $39,950.00; holdings increase to 125,000 shares.

Director Mendoza executed 2 separate purchases totaling 5,000 shares for $39,950.00 at an average price of $7.99, increasing his holdings by 4.2% to 125,000 shares. The blended purchase price of $7.99 is slightly below the current price of $8.19, and notably near the lower end of the 52-week range ($6.73–$15.40), which sits at -46.8% from the 52-week high. His prior 5 trades at HLF show a concerning timing pattern: of 2 measurable same-ticker purchases, neither achieved positive 90-day returns, with outcomes of -14.4% and -13.7% respectively, suggesting limited success in recent accumulation efforts. While this filing represents a small addition to his existing position, the recency of similar underperforming purchases and the stock's significant distance below its 52-week peak warrant attention to whether the director sees value or if the pattern of acquisition at falling prices reflects compounding conviction.

Director Juan Miguel Mendoza bought 10,000 HLF shares at $7.11 on 2024-09-09; stock down -55.7% from 52-week high, holdings now 120,000.

Director Juan Miguel Mendoza purchased 10,000 shares of Herbalife at $7.11 on 2024-09-09, expanding his holdings from 110,000 to 120,000 shares. This buy occurs amid significant price pressure: the stock trades at $6.82 (down -55.7% from its 52-week high of $15.40) and has fallen -22.8% over 30 days and -41.7% over 90 days. His same-ticker history at HLF shows prior buys on 2024-08-26, 2024-08-13, 2024-05-10, 2024-05-09, and 2024-05-08; outcomes on the earlier May purchases (30d +5.4% to +10.4%, but 90d results ranging from -14.4% to -6.2%) reveal a pattern of 0 of 3 prior buys being well-timed at the 90-day mark. The fundamental backdrop shows flat-to-negative trends: net income of $4.7M on $1.3B revenue with annual revenue growth of -2.7%. The recent accumulation in late August and September coincides with persistent weakness, but his historical success rate of 50% on buys across all tickers with a +5.0% average 90-day return does not establish predictive value for this specific ticker's direction.

Director Mendoza buys 10,000 HLF shares at $8.72; stock now $8.39 (-47.0% from 52-week high)

Director Juan Miguel Mendoza purchased 10,000 shares of Herbalife at $8.72 on 2024-08-26, expanding his holdings by 10.0% to 110,000 shares. The purchase occurs in a sharply declining stock environment: HLF is -47.0% from its 52-week high of $15.82 and has fallen -32.8% over the past 30 days, now trading at $8.39. Mendoza has made 5 prior trades at HLF, all buys, with 0 of 4 measurable prior purchases showing positive 90-day returns; his most recent same-ticker buy on 2024-08-13 remains unmeasurable but his four prior HLF buys from May showed 90-day outcomes ranging from -14.4% to -1.6%. His cross-ticker track record across 9 prior open-market buys shows a 50% 90-day win rate with modest average returns (+3.8% at 30 days, +5.0% at 90 days), which does not establish consistent pattern-recognition at this specific security.

Director Juan Miguel Mendoza bought 6,721 shares of HLF at $8.01 on 2024-08-13, bringing holdings to 100,000 shares amid stock down -29.1% in 30 days.

Mendoza purchased 6,721 shares on 2024-08-13 at $8.01, a modest 7.2% addition to his then-93,279 share position, within the context of HLF trading at a current price of $7.98 and down 54.3% from its 52-week high of $17.46. His cross-ticker track record shows an average 90-day return of 5.0% with a 50.00% win rate across 8 prior buys, but at HLF specifically, his 5 prior purchases in May 2024 were largely unsuccessful at the 90-day horizon, with only 1 of 5 well-timed (positive 90d return), and 4 posts showing negative 90-day returns ranging from -1.6% to -14.4%. The stock has declined 29.1% in the 30 days since this purchase and 28.0% over 90 days. The company reported net income of $4.7M on revenue of $1.3B, with annual revenue declining 2.7% year-over-year, and trades at a P/E of 9.85 with a market cap of $803.7M. This purchase follows a pattern of repeated buying at this ticker with historically poor subsequent performance, suggesting either conviction in a contrarian thesis or mechanical accumulation despite deteriorating fundamentals and price momentum.